Overlapping deletion regions at 11q23 in myelodysplastic syndrome and chronic lymphocytic leukemia, characterized by a novel BAC probe set

被引:4
|
作者
Lee, ASG
Rudduck-Sivaswaren, C
Lie, DKH
Chua, CLM
Tien, SL
Morsberger, L
Griffin, CA
机构
[1] Natl Canc Ctr, Div Med Sci, Singapore 169610, Singapore
[2] Singapore Gen Hosp, Dept Pathol, Singapore 0316, Singapore
[3] Johns Hopkins Med Inst, Dept Pathol, Baltimore, MD 21205 USA
基金
英国医学研究理事会;
关键词
D O I
10.1016/j.cancergencyto.2004.01.007
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Translocations or deletions involving the 11q23 region have been observed in acute lymphoblastic leukemia (ALL), acute myelocytic leukemia (AML), myelodysplastic syndrome (MIDS), and chronic lymphocytic leukemia (CLL). BAC probes encompassing the D11S29 and D11S924 markers and flanking the MLL gene were used in dual color fluorescence in situ hybridization. Fifteen patients with hematologic malignancies and cytogenetic abnormalities of 11q23 were analyzed. The BAC and MLL probes demonstrated split signals in five of 7 ALL or AML cases with translocations of 11q23. Of the remaining 2 cases, one had normal signals for both probe sets and the other had a submicroscopic deletion of the MLL 3' region. In one case of AML with del(11)(q23), deletion of the MLL 3' region and the region telomeric to the MLL gene was seen. Three CLL cases with deletion of part or the entire 11q23 region showed deletion of one copy of MLL, but retention of the region telomeric to MLL. However, in four MDS cases with deletions involving the 11q23 region, deletions of both the MLL gene and the flanking regions of the MLL gene were observed. Hence, the deletions on 11q23 are different but overlapping for CLL and MDS, implicating different genes involved for these diseases. (C) 2004 Elsevier Inc. All rights reserved.
引用
收藏
页码:151 / 157
页数:7
相关论文
共 50 条
  • [1] Distinct gene expression profiling in chronic lymphocytic leukemia with 11q23 deletion
    Aalto, Y
    El-Rifai, W
    Vilpo, L
    Ollila, J
    Nagy, B
    Vihinen, M
    Vilpo, J
    Knuutila, S
    LEUKEMIA, 2001, 15 (11) : 1721 - 1728
  • [2] Distinct gene expression profiling in chronic lymphocytic leukemia with 11q23 deletion
    Y Aalto
    W El-Rifai
    L Vilpo
    J Ollila
    B Nagy
    M Vihinen
    J Vilpo
    S Knuutila
    Leukemia, 2001, 15 : 1721 - 1728
  • [3] Secondary acute leukemia and myelodysplastic syndrome with 11q23 abnormalities
    Secker-Walker, LM
    Moorman, AV
    Bain, BJ
    Mehta, AB
    LEUKEMIA, 1998, 12 (05) : 840 - 844
  • [4] Secondary acute leukemia and myelodysplastic syndrome with 11q23 abnormalities
    LM Secker-Walker
    AV Moorman
    BJ Bain
    AB Mehta
    Leukemia, 1998, 12 : 840 - 844
  • [5] Discontinuous deletions at 11q23 in B cell chronic lymphocytic leukemia
    Zhu, Y
    Monni, O
    El-Rifai, W
    Siitonen, SM
    Vilpo, L
    Vilpo, J
    Knuutila, S
    LEUKEMIA, 1999, 13 (05) : 708 - 712
  • [6] Discontinuous deletions at 11q23 in B cell chronic lymphocytic leukemia
    Y Zhu
    O Monni
    W El-Rifai
    SM Siitonen
    L Vilpo
    J Vilpo
    S Knuutila
    Leukemia, 1999, 13 : 708 - 712
  • [7] Increased transferrin receptor expression following 11q23 deletion as a mechanism of malignant progression in chronic lymphocytic leukemia
    Shackelford, RE
    Bhalodia, AI
    Cotelingam, JD
    Veillon, DM
    Lowery-Nordberg, M
    MEDICAL HYPOTHESES, 2006, 66 (03) : 509 - 512
  • [8] 11Q23 ABNORMALITY AND CHRONIC MYELOMONOCYTIC LEUKEMIA
    SANADA, I
    CANCER GENETICS AND CYTOGENETICS, 1988, 30 (02) : 341 - 342
  • [9] Unique gene expression and clinical characteristics are associated with the 11q23 deletion in chronic lymphocytic leukaemia
    Dickinson, JD
    Smith, LM
    Sanger, WG
    Zhou, GM
    Townley, P
    Lynch, JC
    Pavletic, ZS
    Bierman, PJ
    Joshi, SS
    BRITISH JOURNAL OF HAEMATOLOGY, 2005, 128 (04) : 460 - 471
  • [10] CHROMOSOME CHANGES AT 11Q23 AND 17Q11 IN MYELODYSPLASTIC SYNDROME (MDS)
    OHYASHIKI, K
    YOSHIDA, MA
    OHYASHIKI, J
    SANDBERG, AA
    PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, 1985, 26 (MAR): : 31 - 31